US 12,371,667 B2
Enhanced methods for inducing and maintaining naive human pluripotent stem cells
Thorold Theunissen, St. Louis, MO (US); Shafqat Khan, St. Louis, MO (US); and Rudolf Jaenisch, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US); and Whitehead Institute for Biomedical Research, Cambridge, MA (US)
Filed by Washington University, St. Louis, MO (US); and Whitehead Institute for Biomedical Research, Cambridge, MA (US)
Filed on May 13, 2022, as Appl. No. 17/744,266.
Claims priority of provisional application 63/188,308, filed on May 13, 2021.
Prior Publication US 2022/0364060 A1, Nov. 17, 2022
Int. Cl. C12N 5/074 (2010.01); C12N 5/0735 (2010.01)
CPC C12N 5/0696 (2013.01) [C12N 5/0606 (2013.01); C12N 2501/999 (2013.01)] 1 Claim
 
1. A method of maintaining or passaging at least one naïve human embryonic stem cell in the absence of a mitogen-activated protein kinase kinase (MEK) inhibitor, the method comprising:
culturing the at least one naïve human embryonic stem cell in the presence of Tankyrase (TNKS) inhibitor XAV939, Protein Kinase C (PKC) inhibitor Go6983, a Rho-Associated Protein kinase (ROCK) inhibitor comprising Y-27632, and Rapidly Accelerated Fibrosarcoma (RAF) kinase inhibitor AZ628.